I
`
`COMPANY PROFILE
`
`0
`
`~--------------------------------------~~~HIBFf ~6
`INNOPHARMA v SENJU
`PAGE 1 OF 18
`IPR2015-00903
`
`

`
`President's Message
`
`The characters that comprise Senju's company name in the Japanese language are "Sen" and "Ju", which
`
`literally mean "thousand" and "bringing happiness", respectively. Senju, bringing much (a thousand)
`
`happiness, has an objective to bring a "happiness" to the people associated with us through the
`
`development of original pharmaceutical products for the care of the five senses (eyes, ears, nose, throat
`
`and skin), which ultimately improves the joy of living.
`
`This is our management policy; "Good Company".
`
`We strongly believe that Senju should be a trustworthy and essential company by putting ourselves into the
`
`other person's shoes and acting under the Action Guideline; "If I were you".
`
`Yukoh Yoshida
`Presideat & CEO
`
`PAGE20F18
`
`

`
`Management Policy
`
`Good Company
`
`At Senju Pharmaceutical, our mission is to pursue happiness
`for every person associated with the company.
`
`"Being a good company" is our management policy.
`
`As a company that aims to be reliable, necessary, and valuable to society, we are
`committed to pursuing happiness for all people associated with the company, rather than
`simply becoming a "Big Company" that pursues only greater growth and increased sales.
`
`Action Guideline
`
`If I were you
`
`"If I were you"
`Considering others' viewpoints is the starting point for all of our business activities.
`We should not do to others what we would not like to be done to us.
`
`To treat others in a way that would make us happy if we were treated that way, we
`need to think about and do things from others' points of view at all times.
`These are the action guidelines that Senju Pharmaceutical employees aim to follow.
`
`S£NjU SE N SE
`
`SENJU SENSE is a systematic collection of the concepts and values that have
`
`been carefully handed down over the generations since the founding of our
`company, including our Management Pol icy "Good Company". It is a collective
`
`name for Senju's val ues, wh ich are so essential duri ng decision-making and the
`
`execution of our responsibilities. By ensuring that each and every employee
`
`shares our SENJU SENSE and works w ith firm belief in the pursuit of happiness
`for all people associated with the company, we aim to come up w ith a variety of
`innovative new ideas, thereby ensuring that Senju remains a "Good Company".
`
`PAGE3 OF 18
`
`2
`
`

`
`Ethical Products
`for Medical Professionals
`
`As a manufacturer of ophthalmological drugs, Senju Pharmaceutical
`has entered the promising fields on the front lines of medicine.
`
`--
`
`In addition to creating new medicines, particularly
`ophthalmic solutions in the field of eye medicine, Senju
`Pharmaceutical offers a broad range of generic products
`and we steadily implement measures to respond to
`changes in the market environment. What's more, we
`also work hard to develop and promote what's referred to
`as "orphan drugs", which treat rare diseases suffered by
`extremely small numbers of patients.
`Senju Pharmaceutical will take on new challenges every
`day with the aim of "maintaining and improving vision" for
`as many patients as possible by increasing the added
`value of our products by strengthening the information
`gathering and communication capabilities we have built
`up over many years in the field of ophthalmology and by
`accurately identifying treatment needs in the medical
`workplace as well as by enhancing our marketing, sales
`and logistics functions for promoting activities to
`encourage the rapid popularization of our products.
`
`-
`
`-"
`--
`
`,
`
`I
`
`701??
`
`3
`
`PAGE40F18
`
`

`
`M M S (Medical Management Supporter)
`
`For Human, for Medical, for Tomorrow.
`
`Senju Pharmaceutical has developed an MMS
`(Medial Management Supporter) business to provide
`
`various types of support for the operation of eye
`clinics with the aim of contributing to healthcare in
`
`local communities.
`Strong clinic management is essential to providing
`
`high-quality health-care.
`Through MMS we provide support to the many
`
`management challenges faced by ophthalmologists,
`including the handling of reforms to various systems,
`labor management, the fostering of human resources,
`
`the handling of tax issues, building partnerships with
`other facilities, and improving patient satisfaction.
`
`What's more, in order to provide ever-changing
`healthcare Information to ophthalmologists on a
`
`timely basis, we provide information via management
`magazine Medi-Net and our ophthalmologists'
`management information service website.
`
`PAGES OF 18
`
`Management magazine Medi-Net
`
`Architectural models
`
`4
`
`

`
`Over the Counter (OTC) Products
`
`The Mytear brand was developed from our research into tears.
`
`Tears are invaluable to our eyes and they have even
`
`is an over-the- counter product containing
`
`been described as "heaven's eye medicine".
`
`pranoprofen, a nonsteroidal anti-inflammatory drug
`
`Thanks to our ongoing efforts in tear research, in
`
`that has been recognized as an effective and safe
`
`1965 Senju Pharmaceutical launched Japan's first
`
`prescription product.
`
`ever tear-type eye medicine, the artificial tear
`
`Mytear.
`
`Fifteen years later in 1980 we launched Mytear CL
`
`as a contact lens use eye medicine, the first in
`
`Japan that could be applied while still wearin g soft
`
`contact lenses. We have continued to develop eye
`
`medicine under the Mytear brand in response to
`
`changing times and changing user needs.
`
`In recent years, we have utilized our product
`
`development capabilities as a manufacturer of
`
`prescription eye medicine and our many years of
`
`marketing experience to launch unique and high
`
`quality products, including Mytear EYETECT, which
`
`5
`
`PAGE 6 OF 18
`
`

`
`Overseas Activities
`
`When it comes to eye health and the development of
`
`pharmaceutical products, there are no national borders.
`
`Senju Pharmaceutical promotes international
`activities with an eye on the pharmaceutical products
`of tomorrow, beyond the limits of individual countries
`
`or companies.
`As we approach the global age, Senju
`
`SCIENCE & TECHNOLOGY (BEIJING) CO., LTD.
`and local manufacturing and sales company SENJU
`WANHE PHARMACEUTICAL (SHENZHEN) CO., LTD.
`
`We are actively seeking to expand the scope of our
`activities and have established local offices in Russia
`
`Pharmaceutical's overseas activities have become
`more diverse than ever. We have promoted the export
`
`and Vietnam.
`
`of finished products, new product technology and
`patent derivations, and we are now active in more
`than 50 countries. In order to build partnerships and
`
`introduce the latest technologies and information as
`quickly as possible, it is necessary to remain
`
`unconstrained by regional location, industry or scale.
`In the United States, we have established a
`
`subsidiary SENJU USA, INC. with the aim of
`promoting research and development in United
`States pharmaceutical products. In China, we have
`
`established subsidiary SENJU PHARMACEUTICAL
`
`PAGE70F18
`
`6
`
`

`
`Research and Development
`
`We are using our cutting edge technology and unique research
`
`system to pursue the limitless possibilities of people and science.
`
`"All things in nature have a reason for being.
`Today's common sense is not common sense tomorrow:
`This is the motto of our researchers.
`Senju Pharmaceutical pursues research and development
`through flexible thinking without being constrained by
`existing limits or stereotypes through our unique research
`system, which includes international joint research projects
`and collaborative research with industry and academia.
`At the Senju Laboratory of Ocular Science and our Oregon
`Laboratory in the United States, we carry out basic
`
`research into the creation of treatments by using culling
`edge technology to identify the molecules that cause eye
`diseases. At our Kobe Creative Center, we promote
`research that will lead directly to product development,
`including accumulating the data needed for the approval of
`pharmaceutical products. AI of our centers work in close
`cooperation on this research. Our eyes are fixed firmly on
`the future. Our goal and aspiration is to develop the
`pharmaceutical products that are truly needed by society,
`safely and as quickly as possible.
`
`I Kobe Creative Center
`
`I Senju Laboratory of Ocular Science
`
`I Oregon Laboratory, United States
`
`7
`
`PAGE80F18
`
`

`
`Production
`
`Bringing you high quality pharmaceutical products from
`
`factories that meet PIC/S GMP standards
`
`When manufacturing pharmaceutical products, it is
`essential to comply with the GMP (Good Manufacturing
`Practice) standard for the manufacture of phannaceutical
`products and quasi drugs, from delivery of raw materials
`through to shipment of the finished product.
`What's more, because eye medicine is a sterile product,
`there is a need for sterile manufacturing facilities that
`guarantee a high level of sterility, and a need for the
`installation of testing equipment and quality control.
`Senju Phannaceutical worl<s to comply with PIC/s-GMP
`
`standards at an early stage in anticipation of revisions to
`GMP standards. Moreover, we have built a system that
`allows us to implement ongoing improvements to reduce
`our impact on the environment
`We will continue to deliver a steady supply of high quality
`phannaceutical products to Japan and the wortd from
`factories that combine state-of-the-art manufacturing
`facilities with a state-of-the-art manufacturing environment
`
`PICIS: The Pharmaceutical Inspection Convention and
`Pharmaceutical Inspection Co-operation Scheme
`
`I Manufacturing Plant Karatsu
`
`I Manufacturing Plant Fukusaki
`
`Status of 15014001 Certlficallon Acquisition : Plant Fukusaki in December 2007 I Plant Karatsu In December 2014
`
`PAGE9 OF 18
`
`f g .
`
`8
`
`

`
`Animal Health
`
`Using the pharmaceutical technologies developed for
`humans to develop health products for companion animals
`
`People are not the only living things to use sense
`
`organs such as the eyes and ears to collect
`
`abundant information for use in their everyday lives.
`
`Sense organs are also an essential part of the daily
`
`lives of the pets who live side by side with humans.
`
`In recent years, improved living standards and
`
`medical advances have increased the length of time
`
`that pets and humans can live side by side, leading
`
`to increased risk from ageing associated lifestyle
`
`diseases and increased importance of the sense
`
`organs in pets' daily lives. Senju Pharmaceutical has
`
`continued to utilize the pharmaceutical development
`
`technologies we have accumulated over many years
`
`of developing human sensory organ pharmaceutical
`
`products in the development and promotion of animal
`
`pharmaceutical products and other animal products,
`
`·'i-·-'
`
`helping our pets to live long and happy lives.
`
`l l
`
`IIJ
`
`'"
`
`M
`
`•u~u-i:'
`
`'
`W,7~ ·-I -
`
`9
`
`PAGE 10 OF 18
`
`

`
`PAGE 11 OF 18
`
`A1leva'm'r'mfi3rflrz.F‘£wSensu |
`
`MNIUI
`SENJU
`
`PAGE 11 OF 18
`
`

`
`Senju Pharmaceutical Co., Ltd.
`
`2-5-8, H i ran~m achi , Chuo-ku, Osaka
`TEL : 06-6201-2512 (main switchboard)
`FAX : 06-6226.0406
`URL : http://www.senju.co.jp
`
`PAGE 12 OF 18
`
`

`
`Milestones in Our History
`
`1988
`
`1993
`
`1994
`1999
`2000
`2001
`2004
`2006
`
`.Nne Capital inaeased to 1,415,500,000yen.
`Oclob8f NSAID Ophthalmic SokJtioo, "NIA.AN', launched.
`January Los Angeles otfioe opened in USA.
`February Kobe Creative Canter completed.
`May YokOhama Blanch opened.
`.Nne Kobe Branch opened.
`April Chlba Branch and Saltama Blanch opened.
`July NSAID Ophthalmic So~Uon. 'BRONUCK", launched.
`April A laboratory completed In Oregon, USA.
`April The European Office opened.
`April Btrijing Office opened In China.
`April Sooju USA, Inc. establshed.
`April Sooju Laboratory of Ocular Science, Kobe Laboraillly
`completed .
`.Nne Yukoh YotNda becomes the Presideflt of the Company.
`May Sooju Medical Consulting (ShanghaQ Co, Ltd. estatlished in
`Shanghai, China.
`August Osaka Logislleal Warehouse opened.
`DeceiNJer ManufacUing f'lant Karatsu bu'Jt at 4228-1 lshlshl,
`KaralsiHii, Saga.
`Oclober Ophtlbc SokJtion lor Glaucoma Ocular Hypedension.
`"\.UMIGAN', Iaunc:hed.
`2010 N<wemb« Serju Phannactutica.l Scitnce & Tec:Mology (Beijing) Co..
`Ud. established.
`2011 DecenUr Hanoi otfioe opened In Hanoi, VIetnam.
`May Ophthalmic Solution for Glaucoma Ocular Hypertension.
`2012
`•AIPHAGAN', launc:htd.
`December Moscow otfioe opened In Moscow, Russia.
`August Sailama Ofllct opened.
`January Chiba OII'IC8 opened.
`Man:h Shizuoka Salel ite omce opened.
`July Sooju Wanhe Phamlaceutical Shenzhen C«p. eslabished in
`Shenzhen, China as a joint company.
`
`2008
`
`2009
`
`2013
`2014
`
`1947
`
`1949
`
`1951
`
`Ajrl The Company founded at 12~shigalsujkho, Tennoji-lru,
`Osaka. Slart-<JP capital ol195,000 yen. President, Hioshi
`Tsuzukl.
`Jily lnjedion Produc:t for Ne<Jtropenla, 'PANILTIN',Iaunched,
`FebruBIY Relshln Tanlmura becomes lhe President of the Company,
`September Company head olfice relocated to 2-42 Hlranc>machi,
`Hlgash~ku, Osaka.
`Septemb8f MaoofaciiJrlng plant relocated to 482 lwazooc:><:ho, Ashiya City.
`June Agreement ooncluded with Takeda Phamlaceutical Company
`Limited for the sole dlstnootioo of Sooju Products.
`0Cl0b8f Capital increased to 780,000 yen.
`1953
`1955 December Masao Yoslllda becomes the Presideflt of the Company.
`March Capital increased to 3,000,000 yen.
`1957
`A¢1 Tokyo Blanch opened.
`1958 December OphthalmleSolutioo lor Cataracts, 'CATAUN', Iaunc:hed.
`August Capital increased to 6,000,000 yen.
`1960
`lmplemeatatioo ollhe City f'laMing M meant the company
`November
`relocated the Ashlya l'tanl to a nt!'o\ly-bult ,:Aant al416
`lwazono<ho.
`Ajrl Fukualca 8on:h opened.
`May Capilal increased lo 9,000,000 yen.
`August Capilal increased lo 13,500,000 yen.
`December ltaml f'lanl nt\04y bu:l lot the manufad1re of ingredients at 1·1
`Qshb.Sakuragaolta, 118m! City.
`May Capilallncreased lo 18,000,000 yen.
`s.plemblr Laborltory and attached facilities new1y ooilt at the Ashiya
`Plan1.
`May Capital Increased lo 30,000,000 yen.
`Apr! Artificial Tear Ophlhalmic Solulions, 'MYTEAR", Iaunchod.
`May Company head olfice relocated to 1-83 Ooshin-oho,Kita-ku,
`Osaka.
`1967 September Nagoya Branch opened.
`1969 Novtmb8f Capital increased to 75,000,000 yen.
`1970
`~li Sendal Branch opened.
`1971
`JIAy Sapporo Branch opened.
`Ocloblf LaboratOf)' com,:jeted in the ftami Planl
`Marcil Company head office and Osaka Blanch relocated to 3-28
`Hlran()<11achl, Hlgash~ku, Osaka (Amakasu BuJding).
`Apr! Hiroshima Branch opened.
`Aplil Capital increased to 150,000,000 yen.
`June ManufaciiJring Plant Fukusal<l oollat 767·7 KaZtJicanonislli,
`Saijl, Fukusakkllo, Kanzal<>.gun, Hyogo.
`Oclober Capital increased to 225,000,000 yen.
`.Nne Shoji YOShida becomes the Pmldent of the Company.
`Nowmll« Company head olb reb:ated 1o ~1 Hirano-machi,
`Hfgashl-ku, Osaka (7" fbo( of HnncHnadll Centtry Bul)ling).
`February OpNhalmlc Solution lot use on CIOfl!act lens, "MYTEAR a.·.
`launched.
`Ajrl Capital increased lo 450,000,000 yen.
`Jn A boologicallabotatoly completed in the ltani Research
`Laboraillly.
`1984 s.plemblr captal increased to 1,050,000,000 yen.
`Oclober Uts~mmiya Btanch. Matsumoto Branch, and Takamatsu
`Branch opened.
`Apr! Kyolo Branch opened.
`Janu91Y Intraocular nlgating So~llon. "'PE GUARD MA', launched.
`
`1961
`
`1962
`
`1963
`
`1964
`1965
`
`1972
`
`1973
`
`1974
`
`1975
`1978
`
`1980
`
`1981
`1983
`
`1985
`1987
`
`PAGE 13 OF 18
`
`

`
`Company Profile
`
`Trade Name
`Principal Office
`
`Senju Pharmaceutical Co., Ltd.
`2·5·8, Hirano-machi, Chuo-ku, Osaka, 541·0046, Japan
`TEL: +81·6-6201-2512
`FAX: +81-6-6226~6
`Date of Incorporation April, 1947
`Representative
`Yukoh Yoshida
`Capital
`1.4 billion yen
`Employees
`861 (as of March 2015)
`Sales
`35 billion yen (as of March 2015)
`Accounting Period
`March
`(1) Pharmaceutical business: manufacture and sale of prescription eye, ear,
`Business Content
`nose and throat medicines, contact lens solutions and animal medicines
`(2) Other business: manufacture and sale of raw materials for cosmetics
`
`I Matters related to officers
`
`Member of the Board of Directors
`Chairman of the Board
`Shoji Yoshida
`President & CEO
`Yukoh Yoshida
`Shuhel Yoshida
`EMCUtiYe Va President & COO
`Head ol C«porate Managemert OM5m and Business S!rategy DM$on
`M~suyoshi Azuma Managing Excutive Officer
`Head of Laboratory, Senju Laboratory of Ocular Science
`Managing Excutive Officer
`Head of Pharmaceutical Marketing Division
`Corporate Auditor
`
`Takashi Masuda
`
`Akeml Yamasaki
`
`Executive Officer
`Takeshi Sugisawa
`Head of Business Development Division
`Hidemi Shimoji
`Head of Research and Development DMsion
`Mikio Ogawa
`Head of Overseas Business Division
`T omio Maenaka
`Head of Production Division
`Michinarl Wada
`Head of Reliability Assurance Division
`Takahiro Ogawa
`President of SENJU USA (secondment)
`
`I Trends In Sales and Current Profits
`
`Sal es (unit:¥ billion)
`
`Current Profits (unit: ¥ billion)
`
`35.0
`
`30.0
`
`25.0
`
`9.0
`8.0
`7.0
`6.0
`5.0
`
`20.0
`
`4.0
`3.0
`2.0
`1.0
`o L-------~------~--------L-------~------~ 0
`2010
`2012
`2013
`2011
`2014
`
`Sales(unit: ¥ bUiion) ___....__ Current Profits (unit: ¥ bllllon)
`
`Sales
`Current profits
`
`2010
`23.6
`3.0
`
`2011
`25.1
`4.4
`
`2012
`28,6
`
`2.6
`
`2013
`33.0
`5.1
`
`2014
`35.0
`7.4
`
`Unit: Bll ion yen
`
`PAGE 14 OF 18
`
`

`
`Offices (Overseas)
`
`l aboratories and Offices
`
`(SLOS}
`SENJU LABORATORY OF OCULAR SCI ENCES
`OTRADI Bioscience Incubator, 4640 SW Macadam Ave., Suite 200C, Portland, OR 97239, U.S.A.
`Te l: +1-503-748-6202
`Fax: +1-003-746-6204
`
`e sENJU PHARMACEUTICAL CO., LTD. BEIJI NG OFFICE
`Unit 3602, Fortune Plaza Office Tower A, No.7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C
`Tel: +86-10~533-0200
`Fax: +86-10~536-1329
`e sENJU PHARMACEUTICAL CO., LTD. Hanoi Representative Office
`Room 1314, Level 13, Ha Nol Towers, 49 Hal Ba Trung, Hoan Kiem District, Ha Noi, Vietnam
`T e 1: +84-4-3934-3890
`Fax: +84-4-3934-3966
`e Moscow Representative Office of Senju Pharmaeeutleal Co., ltd,
`Office No.105, 1st floor, str. 6, dom 1A, Tretiy Nizhnetikhoborskiy proyezd, Moscow 125371, Russian Federation
`
`Subsidiaries
`
`e sENJU USA, INC.
`21700 Oxnard Street, Suite 1070 Woodland Hills, CA 91367, U.S.A.
`Te l: +1-818-719-7190
`Fax: +1-818-719-7195
`
`e sENJU PHARMACEUTICAL SCIENCE & TECHNOLOGY (BEIJING) CO., Lm.
`Unit 3602, Fortune Plaza Office Tower A. No.7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C
`Te 1: +86-1 0~533-0200
`Fax: +86-10~536-1329
`
`e sENJU WAN HE PHARMACEUTICAL (SHENZHEN) CO., LTD.
`Block B, Wanhe Technology Complex, HI-tech Park, Guangming District, Shenzhen, Guangdong Province, China
`
`PAGE 15 OF 18
`
`

`
`Offices (Japan)
`
`I Head Office
`
`Hirano-machi Century Building
`2-5-8, Hirano-machi, Chuo-ku, Osaka, 541 -0046
`TEL: +81-6-6201-2512 (main switchboard) FAX: +81 -6 -6226-0406
`
`I Branches and Groups
`
`[Northern Japan Branch]
`e sapporo Office, Sapporo Group
`Takeda Sapporo Building,
`13-4, Kltalchljonlshl, Chuo-ku, Sapporo-shl, Hokkaldo, 060-0001
`TEL: +81-11-221-2743
`
`[Tokai Branch]
`• Nagoya Office, Tokal First Group, Tokal Second Group
`Nishikl Park Building
`2-4· 3, Nishiki, Naka-ku, Nagoya-shl, Alchi, 460-0003
`TEL: +81· 52· 211-2560
`
`e Sendal Office, Tohoku FlrJt Group, Tohoku Second Group
`Takeda Sandal Building
`2-18-21 , Honcho, Aoba-lc.u, Sendal-shl, Miyagi, 980-0014
`TEL: +81-22-264-2288
`
`(Saitama Kltakanto Shlnetsu Branch]
`• utsunomlya Offlca, Klta-Kanto Group
`Chuo Utsunomlya Building
`3-1-1, Hlgashlshukugo, Utsunomlya-shi, Tochigi, 321-0953
`TEL: +81·28-633·6250
`
`e saltama Office, Sa llama Group, Shlnetsu Group
`82 Omiya Building
`1-11-3, Sakuraglcho, Omlya-ku, Saitama-shi, Saitama, 330-0854
`TEL: +81 ·48-658·2340
`
`(Kanto Branch]
`. Chlba Office, Chlba Group
`La laport Mitsui Building
`2-1-1 , Hamacho, Funabashi-shi, Chiba, 273-0012
`TEL: +81-47-431-1238
`
`• Tokyo Office, Tokyo First Group, Tokyo Second Group, Tokyo Third Group
`M FPR Nlhonbashlhoncho Building
`3-7-2, Nihonbashlhoncho, Chuo-ku, Tokyo, 103-0023
`TEL: +81-3-5643-1950
`
`e vokohama Office, Yokohama Group
`Hlgashitotsuka West Building
`90- 6, Kawakamlcho, Totsuka-ku, Yokohama-shi, Kanagawa, 244·0805
`TEL: +81-45- 828-1381
`
`• Shizuoka Satellite Office, Tokai First Group (Shlzuoka base)
`Mitsui Seimel Shlzuoka-eklmae Building
`11-7, Kuroganecho, Aoi-ku, Shizuoka·shl, Shlzuoka, 420-0851
`TEL: +81 · 52· 211-2560 (Nagoya Otflce)
`
`(Kansal Shikoku Branch]
`e Kyoto Office, Kyot o Group
`Sumitomo Seimei Kyoto Buiding
`62, Tsukihokocho, Shinmaehihigashllru, Shijodori,
`Shimogyo-ku, Kyoto-shl, Kyoto, 600-8492
`TEL: +81 -75-229-6549
`
`e o.aka Office, Osaka First Group, Osaka Second Group
`Takeda Hirano-machi Building
`2-4-9, Hirano-machi, Chuo-ku, Osaka, 541-0046
`TEL: +81 · 6 -6226- 0403
`
`e Kobe Office, Kobe Group
`Kobe ltomachi Building
`121, ltomachi, Chuo-ku, Kobe-shl, Hyogo, 650-0032
`TEL: +81-78-321-0475
`
`e Takamatsu Office, Shikoku Group
`Takamatsu Oaiichi Seimei Building
`1-3-2, Kotobuklcho, Takamatsu-shl, Kagawa , 760-0023
`TEL: +81· 87- 822- 9492
`
`[Kyushu Chugoku Branch]
`e Hiroshlma Office, Chugoku Group
`Takeda Hiroshima Building
`1-25, Komachl, Naka-ku, Hiroshima-shl, Hiroshima, 730-0041
`TEL: +81·82-248-2023
`
`e Fukuoka Office, Kyushu First Group, Kyushu Second Group
`Fukuoka Takeda Building
`9 -12, Shimokawabatamaehi, Hakata-ku, Fukuoka-shi, Fukuoka, 812-0027
`TEL: +81 · 92-271-2390
`
`I Manufacturing Plants and Research Laboratories
`
`Manuf aeturlnC P1ant Karatsu
`4228-1, lshlshl, Karatsu-shl, Saga , 847-0832
`TEL: +81-955-78-1050
`
`ManufaeturinC Plant Fukusaki
`767-7, Saljl, Fukusaklcho, Kanzak>-gun, Hyogo, 679-2285
`TEL: +81-790-22-2671
`
`Kobe Creative Center
`1-5·4 , Murotani, Nishi-ku, Kobe-shl, Hyogo, 651-2241
`TEL: +81-78-997-1010
`
`Senju Laboratory of Ocular Science
`BMA
`1-5 -5, Minatojimamlnamlmachl, Chuo-ku, Kobe-shl, Hyogo, 650-0047
`TEL: +81 ·78-303-4031
`
`PAGE 16 OF 18
`
`

`
`Products (Overseas)
`
`I Asia
`
`China
`¢ Pranopulln (Senju)
`e catalln (Senju)
`
`O Bronuck (Senju)
`()Sodium Hyaluronate (Senju)
`
`* Talymus (Senju)
`
`South Korea
`¢ Pranopulin (JW Shinyak)
`
`"trlomenon (JW Shlnyak)
`O Timobetaloi-LA (Taejoon)
`
`C.IBronuck (Taejoon)
`• senju CL (JW Pharma)
`• Frenz Eye Drops (JW Pharma)
`
`Hong Kong
`
`e catalin (Takeda Hong Kong)
`
`Taiwan
`e catalin K (Takeda Taiwan)
`
`Philippines
`
`e catalin (Takeda Philippines)
`
`lndonula
`e catalin (P.T. Takeda Indonesia)
`
`Thailand
`e catalin (Takeda Thailand)
`
`Paklatan
`e catalln (Helix)
`
`VIetnam
`O Bronuck (Senju)
`()Tearbalance (Senju)
`
`India
`O GiucotlmLA (Centaur)
`
`O Ocubro (Centaur)
`
`I Americas
`
`United Statu
`
`O lstalol (B+L)
`O Prolensa (B+L)
`0 Bromday (B+L)
`
`0 Bepreve (B+L)
`0 Durezol (Alcon)
`
`Muleo
`
`¢ Niftan (SIFI)
`
`Brazil
`
`Puerto Rico
`
`e a&rvisol (AIIergan)
`
`0 Dunszol (Alcon)
`
`Canada
`0 Durezol (Alcon)
`
`..
`&.
`~
`'0 a
`~ ""
`
`V> "' ~
`
`c
`
`(')
`0
`
`3: ;;:
`z
`-<
`-..: "' 0 ..,
`;::;
`"'
`
`I Europe and the Middle East
`
`Poland
`e catalln (Pharmaheads)
`
`0 Yelox (Valeant)
`
`Romania
`¢ PranoRog (SIFI)
`
`Belgium
`
`<>Pranox (MEDA)
`
`Portugal
`
`e c larvisan (LUSO)
`0 Yelox (Valeant)
`
`Italy
`
`e crarvisan (Allergen)
`¢ Pranonog (SIFI)
`
`0 Yelox (Valeant)
`
`Ruula
`
`e catalin (Senju)
`
`Germany
`
`O Yellox (Valeant)
`
`United Kingdom
`
`O Yellox (Valeant)
`
`Austria
`
`O Yellox (Valeant)
`
`Franco
`0 Yellox (Valeant)
`
`Hotherllnda
`::::IYellox (Valeant)
`
`Republic of Ireland
`
`O Yellox (Valeant)
`
`Bulgaria
`
`O Yelox (Valeant)
`
`Sweden
`O Yellox (Valeant)
`
`Hungary
`
`O Yelox (Valeant)
`
`Norway
`O Yellox (Valeant)
`
`Swltrtrllnd
`
`O Yelox (Valeant)
`
`Saudi Arabia
`
`e catalin (Saudi Arabian Drug Store)
`
`Denmark
`O Yellox (Valeant)
`
`Finland
`
`O Yellox (Valeant)
`
`Spain
`
`O Yellox (Valeant)
`
`Product names In Jopon: e CATALIN * LOMEFLON 0 NIFLAN 0 BRONUCK 0 TEARBALANCE * TALYMUS • Generic medicine 0 Not sold in Japan
`
`*O=Marketlng Authorization Holder
`
`As of July 20t5
`
`PAGE 17 OF 18
`
`

`
`Products (Japan)
`
`I Prescription Products
`
`(Eye products]
`
`Cataracts
`
`Other
`
`ARTIFICIAL TEAR MYTEAR OPHTHALMIC SOLUTION
`SCOPISOL SOLUTION FOR EYE
`SOFTEAR OPHTHALMIC SOLUTION 0.02%
`
`TAZIN TABLETS 30
`TALYMUS OPHTHALMIC SUSPENSION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.3%
`
`TEARBALANCE MINIMS OPHTHALMIC SOLUTION 0.3%
`
`(Ear, nose and throat prod uct s]
`
`VISUALIN SOLUTION FOR EYE EAR AND NOZE 0.1%
`BESTRON FOR EAR AND NOSE 1%
`LOMEFLON SOLUTION FOR EAR 0,3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`Inflammation and allergy
`
`ELICS OPHTHALMIC SOLUTION 0,25%
`ODOMEL OPHTHALMIC SOLUTION 0.02%
`ODOMEL OPHTHALMIC SOLUTION 0.05%
`
`ODOMEL OPHTHALMIC SOLUTION 0,1%
`CROMOFERON OPHTHALMIC SOLUTION 2%
`KETAS OPHTHALMIC SOLUTION 0.01%
`
`NIFLAN OPHTHALMIC SOLUTION 0,1%
`VISUALIN OPHTHALMIC SOLUTION 0.02%
`VISUALIN OPHTHALMIC SOLUTION 0.05%
`
`VISUALIN SOLUTION FOR EYE EAR AND NOSE 0.1%
`BRONUCK OPHTHALMIC SOLUTION 0.1%
`LYSOTEAR OPHTHALMIC SOLUTION 0.5%
`LEVOCABASTINE 0.025% OPHTHALMIC SOLUTION (TSJ
`
`Antibacterial and antifungal agents
`GATIFLO OPHTHALMIC SOLUTION 0.3%
`
`BACCIDAL OPHTHALMIC SOLUTION 0,3%
`PIMARICIN 1% Ointment (SENJU]
`PIMARICIN OPHTHALMIC SOLUTION 5% (SENJU]
`
`BESTRON OPHTHALMIC SOLUTION 0,5%
`LOMEFLON OPHTHALMIC SOLUTION 0.3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`CATALIN FOR OPHTHALMIC 0,005%
`CATALIN·K FOR OPHTHALMIC 0.005%
`
`Glaucoma
`
`AIPHAGAN OPHTHALMIC SOLUTION 0.1%
`MIKELAN OPHTHALMIC SOLUTION 1%
`MIKELAN OPHTHALMIC SOLUTION 2%
`
`MIKELAN LA OPHTHALMIC SOLUTION 1%
`MIKELAN LA OPHTHALMIC SOLUTION 2%
`LATANOPROST OPHTHALMIC SOlUTION 0.005% SENJU
`
`LUMIGAN OPHTHALMIC SOLUTION 0.03%
`
`Surgical aids
`INDOMELOL OPHTHALI.IIC SOLUllON 0.5%
`OX!UifROCII£ HYWOCilOitOf !I~S OPHIIW.WIC SOlUTION 0.4% ~EJIJU]
`OPEGUARD·MA INTRAOCULAR IRRJGAllNG SOLUTION
`OPEGUARD Neo Kit l'lTRAOOJLAR IRRJGAllNG SOLIIIlllll 0.0184%
`OPE LEAD 0.5 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD O.S OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPE LEAD 1.1 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD HV0.4 OPHTHALIIIC VISCOELASTK: PREPARATION 1%
`OPELEAD HV0.6 OPHTHALIIIC VISCOELASTK: PREPARATION 1%
`
`OPELEAD HV0.850PHTHALMIC VISCOELASTIC PREPARATION 1%
`
`I Over the Counter (OTC) Products
`
`I Contact Lens Products
`
`Eye medicine
`
`Mytear EYETECT
`Mytear EYETECT ALPITATTO
`
`Mytear EYETECT ALPITATTO.N
`Mytear ALPITATTO EXa
`Mytear ALPITATTO • EX a
`NewMytearA
`MytearCiean Cool
`Mytear Vitamin B,S.E
`
`MytearVido
`Mytear Fresh40
`
`Eye medicine for use with contact lens
`
`O,jhard use
`
`NewMytear CL a
`NewMytear CL Cool a
`
`NewMytear Cl Cool HI a
`NewMytear CL Ice Crush
`FirstMytear CL-P
`
`FlrstMytear CL·G
`FirstMytear CL·B
`
`Mytear Hard l.et1s W~ Solution {de~gnated quasi-<lrug)
`NewMytear Easy S
`NewMytear Cl o, Lens care
`
`I Animal Medicines
`
`I Animal Quasi-Drugs
`
`I Animal Health Products
`
`STEROP
`
`TEAROSE
`PAPITEIN
`MIMIENA
`
`LIGHT CLEAN
`LOMEWON
`ONE CLEAN
`
`PAGE 18 OF 18
`
`BEST FRIENDS EAR CLEANER A
`
`BEST FRIENDS EAR CLEANER G
`
`BEST FRIENDS RINSE IN SHAMPOO
`
`BEST FRIENDS TREATMENT MIST TYPE
`
`As of July 2015